Latest News

Eribulin superior to dacarbazine in advanced liposarcoma


Key clinical point: Eribulin is superior to dacarbazine in improving outcomes in advanced liposarcoma.

Major finding: Overall survival with eribulin was 15.6 months versus 8.4 months with dacarbazine (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P less than .001).

Data source: Phase 3 randomized, prospective clinical trial that included 452 patients with advanced liposarcoma.

Disclosures: The study was supported by Eisai. Dr. Demetri and several of the coauthors report relationships with industry including Eisai.




In patients with advanced liposarcoma, eribulin was superior to dacarbazine in improving both overall and progression-free survival, investigators report.

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge

Next Article: